Precision oncology for pancreatic cancer in real-world settings

Implementation of precision oncology in treatment of pancreatic cancer is difficult. Many reasons exist for this problem: first, a rapidly progressive disease, mandating early induction of systemic therapy if at all possible; second, a relatively low number of actionable genetic variations; and third, disappointing results of the vast majority of trials assessing targeted approaches in a general population of patients with pancreatic ductal adenocarcinoma. 1 Chantrill LA Nagrial AM Watson C et al. Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial. Clin Cancer Res. 2015; 21: 2029-2037 Crossref PubMed Scopus (173) Google Scholar Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trialThese real-world outcomes suggest that the adoption of precision medicine can have a substantial effect on survival in patients with pancreatic cancer, and that molecularly guided treatments targeting oncogenic drivers and the DNA damage response and repair pathway warrant further prospective evaluation. Full-Text PDF